Home News Car-T vs. Bispecifics for Lymphoma: Using the Evidence to Sequence Treatments back to News
minute read
CU Cancer Center member Manali Kamdar, MD, associate professor of medicine-hematology at CU School of Medicine, outlined an evidence-guided approach to sequencing CAR-T and bispecific antibody treatments in this population.
Topics: Press Coverage
1665 North Aurora Court
2004
Aurora, CO 80045
720-848-0300
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.
